Abstract | BACKGROUND: METHODS: RESULTS: Before treatment, the C3-activation capacities (C3-AC) in plasma from patients with Crohn disease were comparable with values obtained from healthy controls. The classical C pathway-mediated C3-AC, mannan-binding lectin C4-AC, leucocyte count, C-reactive protein concentration and Crohn Disease Activity Index decreased significantly 8 weeks after the first infusion of Infliximab (P < 0.04, Wilcoxon test). CONCLUSIONS: Before treatment, all three C pathways were within the normal range in plasma from patients with Crohn disease; the decrease observed in the classical pathway-mediated C3-AC after treatment with Infliximab reflects a general down-regulation in immune activation.
|
Authors | E Zimmermann-Nielsen, J Agnholt, O Thorlacius-Ussing, J F Dahlerup, G Baatrup |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
Vol. 38
Issue 10
Pg. 1050-4
(Oct 2003)
ISSN: 0036-5521 [Print] England |
PMID | 14621279
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Complement C3
- Complement C4
- Gastrointestinal Agents
- C-Reactive Protein
- Infliximab
|
Topics |
- Adolescent
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- C-Reactive Protein
(analysis)
- Complement Activation
(immunology)
- Complement C3
(immunology)
- Complement C4
(immunology)
- Complement Pathway, Classical
- Crohn Disease
(drug therapy, immunology)
- Down-Regulation
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Infliximab
- Leukocyte Count
- Male
- Middle Aged
|